ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AUXL Stock Price » AUXL Stock News

Auxilium Pharmaceuticals Share News

 Auxilium Pharmaceuticals (mm) Stock Price
AUXL Stock Price
 Auxilium Pharmaceuticals (mm) Stock Chart
AUXL Stock Chart
 Auxilium Pharmaceuticals (mm) Stock News
AUXL Stock News
 Auxilium Pharmaceuticals (mm) Company Information
AUXL Company Information
 Auxilium Pharmaceuticals (mm) Stock Trades
AUXL Stock Trades

Auxilium Shares Get Lift As Wait For FDA Approval Ends

By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- Shares of Auxilium Pharmaceuticals Inc. (AUXL) are up 11% after the drug maker received Food and Drug Administration approval for Xiaflex in treating a hand disorder late Tuesday. The Malvern, Pa., biotech, has been waiting for an agency decision since the Fall after getting the positive recommendation of an FDA panel of outside experts in September. The initial target date for the approval was prior to the panel, which added a level of uncertainty to the timing of the agency's final decision for both Wall Street and the company. "We were set to go back in the second half of last year," Auxilium President and Chief Executive Armando Anido said in a recent interview. After printing labels and making final preparations, the company plans to launch the drug in late March using about 100 sales representatives. In waiting for regulators to make a decision, the company has been building inventory of Xiaflex. "At this point I think we are as ready as you can get," Anido said. Shares of Auxilium recently traded up 14% to $31.94 on more than five-times is usual volume. "We view Xiaflex as one of a handful of innovative, highvalue biologics and expect AUXL shares to outperform as investor's gain confidence in the drug's commercial success," analyst Eric Schmidt with Cowen & Co., wrote in a note to clients. Schmidt estimates U.S. sales of the drug being $30 million in 2010 and rising to $420 million in 2014. Auxilium will sell the drug itself in the U.S., and its overseas partner Pfizer Inc. (PFE) has already filed for approval in Europe. Auxilium already sells Testim, a topical testosterone gel, and reported total revenue of $125.4 million in 2008. Xiaflex, an enzyme that breaks down collagen, treats Dupuytren's contracture, a buildup of collagen in the hands that can prevent extension of the fingers. The approval of the drug requires a post-approval plan for evaluating and reducing any risk associated with the drug, including a communication plan, medication guide, and providing instructions for properly using the drug. -By Thomas Gryta, Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com

Stock News for Auxilium Pharmaceuticals (AUXL)
DateTimeHeadline
03/05/201513:17:02Amended Tender Offer Statement by Issuer (sc To-i/a)
02/18/201506:09:02Amended Statement of Ownership (sc 13g/a)
02/17/201510:33:04Statement of Ownership (sc 13g)
02/17/201510:16:52Amended Statement of Ownership (sc 13g/a)
02/13/201506:01:30Amended Statement of Ownership (sc 13g/a)
02/10/201517:00:56Statement of Ownership (sc 13g)
02/10/201515:04:28Amended Statement of Ownership (sc 13g/a)
02/09/201517:06:49Termination of Registration of a Class of Security Under Section...
02/04/201516:34:39Amended Statement of Ownership (sc 13g/a)
02/04/201512:20:56Amended Tender Offer Statement by Issuer (sc To-i/a)
02/03/201512:02:21Tender Offer Statement by Issuer (sc To-i)
02/02/201517:03:20Statement of Changes in Beneficial Ownership (4)
01/30/201516:56:30Amended Current Report Filing (8-k/a)
01/30/201511:21:30Amended Statement of Ownership (sc 13g/a)
01/30/201509:40:51Statement of Changes in Beneficial Ownership (4)
01/30/201509:40:03Statement of Changes in Beneficial Ownership (4)
01/30/201509:39:08Statement of Changes in Beneficial Ownership (4)
01/30/201509:38:12Statement of Changes in Beneficial Ownership (4)
01/30/201509:37:24Statement of Changes in Beneficial Ownership (4)
01/30/201509:36:33Statement of Changes in Beneficial Ownership (4)

Auxilium Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad